Home
Don't miss out
Subscribe to STAT+ today, for the best life sciences journalism in the industry
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
for the latest news and insights in the world of life sciences, medicine, biotech, and pharma
at exclusive live and virtual events hosted by STAT
with subscriber-only newsletters delivered to your inbox daily
with our premium data tools
By Lev FacherMarch 21, 2024
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.
The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.
advertisement
But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.
Get unlimited access to award-winning journalism and exclusive events.
Addiction Reporter
Lev Facher covers the U.S. addiction and overdose crisis.
addiction
opioids
STAT Breakthrough Summit
STAT+
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect
To submit a correction request, please visit our Contact Us page.
advertisement
Reporting from the frontiers of health and medicine
Company
Account
More
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Unlimited access to essential biotech, medicine, and life sciences journalism
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Your go-to source for the latest news and insights on biopharma and the life sciences
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Unlimited access to essential biotech, medicine, and life sciences journalism
Become a STAT+ subscriber today!
Become a STAT+ subscriber today!
Your go-to source for the latest news and insights on biopharma and the life sciences